

Effect of High-Dose Direct Anticoagulant Drugs and DOAC-Remove™ on Lupus Anticoagulant Detection by a Hexagonal Phase Phospholipid Assay

Abstract: PB1147

Mushfiqur Rahman, Ali Sadeghi-Khomami, Karen M. Black: Precision BioLogic Inc., Dartmouth, Nova Scotia, Canada

Presented at ISTH 2023, June 24–28

PrecisionBioLogic

Background

Direct oral anticoagulants (DOACs) and Argatroban are known to interfere with Lupus Anticoagulant (LA) testing. *crvocheck*™ Hex LA™ is a hexagonal phase phospholipid neutralization test (HPNT) with a heparin neutralizer.¹ LA is detected in citrated plasma samples by a Delta Correction (Δ CT) of a prolonged APTT using hexagonal phase phospholipid.

Previously, we reported that Dabigatran (200 ng/mL) and Rivaroxaban (400 ng/mL) did not diagnostically impact the assay, although DOACs could prolong the clotting times (CTs) and Δ CT of LA-positive samples.² The capacity and diagnostic compatibility of DOAC-Remove, an activated charcoal anticoagulant neutralizer,³ in treating samples prior to testing by the Hex LA assay is unknown.

Objective

To evaluate the effect of high-doses of direct anticoagulant drugs (500 ng/mL and 1000 ng/mL) on the detection of LA by *crvocheck* Hex LA, with and without DOAC-Remove treatment.

Methods

LA-positive plasma was pooled from three unique donors who tested positive for lupus anticoagulant by multiple assays. LA-negative plasma was pooled from 21 unique normal donors.

LA-negative and LA-positive pooled plasma samples were spiked at two final concentrations of 500 ng/mL and 1000 ng/mL for each of Argatroban, Dabigatran, Apixaban, Edoxaban, and Rivaroxaban (Table 1).

Each sample was tested seven times using the Hex LA assay (Precision Biologic, Dartmouth, Canada) on a Stago STA-R Evolution analyzer, with and without DOAC-Remove (5-Diagnostics, Switzerland) treatment per manufacturers' instructions.

DP-Filter, a DOAC filtration device, was also used in our pre-evaluation study. However, its DOAC neutralization performance was inferior to DOAC-Remove and further evaluation was not performed.

Results

In the absence of anticoagulant drugs, the effect of DOAC-Remove treatment vs. non-treatment on Δ CT was not statistically significant ($p < 0.05$) for either neat LA-negative (2.0 vs 2.9 seconds) or LA-positive samples (31.5 vs 29.9 seconds). This indicates that DOAC-Remove does not adversely impact the LA analytical sensitivity of the Hex LA assay.

Direct anticoagulants increased the Δ CT results in a dose-dependent manner; the increase was noticeably higher in LA-positive samples compared to LA-negative, with Dabigatran having the largest Δ CT increase for both sample types (Table 2).

Table 1.

Anticoagulants tested, with final concentrations in plasma vs. reported peak concentration from PK studies.

Anticoagulant tested	Tested anticoagulant concentrations (ng/mL)	95 th percentile, anticoagulant peak concentration* (ng/mL) ^{4,5}
Argatroban	500, 1000	538.6
Dabigatran	500, 1000	443
Apixaban	500, 1000	321
Edoxaban	500, 1000	250
Rivaroxaban	500, 1000	419

*All were determined by HPLC-MS/MS, except Argatroban (C_{max} mean) which was measured by HPLC-fluorescence assay

Conclusions

Hex LA accurately detected LA even in the presence of high-dose direct anticoagulants (500–1000 ng/mL). However, the presence of such anticoagulant drugs can increase the Δ CT values, which may approach the assay cut-off.

In this *in vitro* research study, DOAC-Remove mitigated CT prolongation caused by direct anticoagulant drugs and reverted Hex LA results to those observed in the absence of such drugs in both LA-negative and LA-positive plasma samples. Thus, LA detection by the Hex LA assay is compatible with plasma samples treated with DOAC-Remove.

References

1. *crvocheck* Hex LA™ Instructions for Use. Precision Biologic Inc.; 2023.
2. Colin Douglas, Rachel Clarke, Navya Kesavan, Derek Lamont, Ali Sadeghi-Khomami, Amanda Wood, and Karen M. Black. *Comparison of Hexagonal Phase Phospholipid Neutralization Assays for Lupus Anticoagulant Detection*. Presented at THSNA Summit (October 2020).
3. DOAC-Remove™ Instructions for Use. 5-Diagnostics.; 2023.
4. B.T. Samuelson, A. Cuker, *Blood Reviews* 2017, 31, 77.
5. Swan SK, Hursting MJ, *Pharmacotherapy* 2000, 20, 318.

Table 2.

Hex LA assay results of plasma samples containing high-dose of direct anticoagulants, without and with DOAC-Remove treatment.

The addition of direct anticoagulants to both LA-negative and LA-positive plasma samples increased clot times measured for the Start and Correct components of the Hex LA assays.

The increase in CT was found to be more pronounced in LA-positive samples across all anticoagulant drugs tested (Figure 1).

Plasma type	Anticoagulants	Concentration (ng/mL)	Hex LA Δ CT (Mean \pm SD, N=7)	
			Without DOAC-Remove	With DOAC-Remove
LA-negative	Argatroban	500	7.1 \pm 2.7	2.1 \pm 1.2
		1000	9.0 \pm 2.0	2.6 \pm 1.6
	Dabigatran	500	13.5 \pm 2.8	2.1 \pm 0.9
		1000	16.4 \pm 2.5	2.8 \pm 1.3
	Apixaban	500	5.2 \pm 1.2	3.0 \pm 1.5
		1000	4.6 \pm 2.1	2.2 \pm 1.4
Edoxaban	500	7.8 \pm 1.3	1.2 \pm 1.0	
	1000	6.2 \pm 1.1	1.3 \pm 1.1	
Rivaroxaban	500	7.6 \pm 2.0	2.9 \pm 2.0	
	1000	9.2 \pm 3.0	1.6 \pm 1.7	
LA-positive	Argatroban	500	72.9 \pm 1.9	32.8 \pm 1.7
		1000	85.9 \pm 7.2	32.8 \pm 3.1
	Dabigatran	500	117.8 \pm 7.7	27.0 \pm 5.6
		1000	150.1 \pm 3.2	32.3 \pm 2.9
	Apixaban	500	50.2 \pm 4.3	30.3 \pm 2.4
		1000	69.0 \pm 3.9	31.1 \pm 1.9
Edoxaban	500	68.8 \pm 4.2	30.8 \pm 3.2	
	1000	83.4 \pm 5.9	30.5 \pm 2.1	
Rivaroxaban	500	77.9 \pm 10.8	31.8 \pm 2.3	
	1000	109.4 \pm 6.7	31.1 \pm 1.6	


Figure 1.

Hex LA Start, Correct, and Delta CT Results (N=7) of various direct anticoagulants.

Plasma samples containing 500 ng/mL and 1000 ng/mL anticoagulants were tested using the *crvocheck* Hex LA kit.

In this study, which examined *in vitro* contrived plasma samples spiked with anticoagulant drugs, DOAC-Remove prevented the prolongation of CT and Δ CT caused by DOAC interference in both LA-negative and LA-positive samples in the Hex LA assay.

The effect of DOAC-Remove was observed at both 500 ng/mL and 1000 ng/mL concentrations for all anticoagulant drugs tested in this study.



Lines in red represent regression analysis of data for LA-negative samples (●).

Lines in blue represent regression analysis of data for LA-positive samples (▲).

The shaded gray zone shows 95% confidence interval.

The assay cut-off (Δ CT 7 seconds) is shown as a black dashed line.